Scipio Bioscience SAS

https://www.scipio.bio

LinkedIn: https://www.linkedin.com/company/scipio-bioscience

Scipio bioscience develops a new generation of single-cell sequencing solutions, to answer the growing needs of clinical and basic research labs. The patented technology is based on an innovative chemical approach conceived by its President and Co-Founder, Prof Stuart Edelstein, a world-renowned biophysicist. Pierre Walrafen, PhD, CEO and Co-Founder of Scipio Bioscience, directs a team composed of scientists with expertise in molecular biology, chemistry, and bioinformatics. The company, hosted in the iPEPS-ICM incubator of the Brain & Spine Institute (ICM, PitiéSalpêtrière Hospital, Paris), has developed the protocol from the initial proof-of-concept studies to a prototype kit ready for beta-testing by collaborating research teams. Scipio bioscience was supported by a grant from the Région Île-de-France and the Programme d’Investissement d’Avenir, operated by BPI France. *

	Start	2017-01-01 established (approx)
	Industry	sample preparation (technology)
	Industry 2	single cell analysis
	Person	Edelstein, Stuart (Scipio Bioscience 201711 President + Scientific Founder)
	Person 2	Walrafen, Pierre (Scipio Bioscience 201711 CEO)

	Region	Paris
	Country	France
	Street	29 Rue du Faubourg Saint-Jacques Pépinière Paris Santé Cochin
	City	75014 Paris
	Tel	+33-1-8916-6603
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Scipio Bioscience SAS. (2/25/20). "Press Release: Scipio Bioscience Raises €6.0 M Series A Financing". Paris.

		Record changed: 2024-03-30